-
Clover Biopharma’s SCB-219M Shows Promising Phase I Results for Chemotherapy-Induced Thrombocytopenia
•
Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its Phase I clinical study of SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) developed in-house. The study, which focused on safety, efficacy, and pharmacokinetics, involved tumor patients undergoing chemotherapy. In the Phase I trial, nine chemotherapy-treated…
-
Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
•
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT) this week, following the clearance of the last regulatory requirement last month. As part of the acquisition, Lilly gains access to Point’s PNT2002, a PSMA-targeting radiopharmaceutical currently in Phase III trials for metastatic castration-resistant prostate…
-
Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment
•
Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate (ADC) HLX42 has received fast-track designation from the U.S. Food and Drug Administration (FDA). The drug is being co-developed with its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) and Suzhou-based Medilink Therapeutics, specifically targeting advanced…
-
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
•
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm PersonGen BioTherapeutics (Suzhou) Co., Ltd. to collaboratively develop in vivo chimeric antigen receptor (CAR)-T cell therapies utilizing CATUG’s mRNA-lipid nanoparticle (LNP) technology for global markets. As of November 2023, a total of ten CAR-T therapies…
-
Cryofocus Biotechnology Secures NMPA Approval for Cryotherapy Equipmen
•
Shanghai-based Cryofocus Biotechnology Co., Ltd. (HKG: 6922) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its cryotherapy equipment, which supports its innovative frozen adhesion treatment system. The cryotherapy equipment comprises a main unit, a foot switch, and an exhaust pipe, and is…
-
Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela (trilaciclib), enabling the transfer of its manufacturing technology from G1 Therapeutics to Simcere’s facility in Hainan. This transition paves the way for localized production of the CDK4/6 inhibitor, enhancing patient accessibility across the region. Trilaciclib,…
-
Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges
•
Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its “Chengda Pharma Shanghai Institute of Pharmaceutical Research Project.” The company cited unfavorable macroeconomic conditions and its operational status as the primary reasons for this decision. The excess funds raised for the project will be retained…
-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
